About The T1D Fund, A Breakthrough T1D Venture

Driving cure-oriented therapies for type 1 diabetes through equity investments in mission-driven companies

Our Mission

A Scaled Venture Fund Catalyzing Cures for Type 1 Diabetes

The T1D Fund launched in 2016 as an independently run subsidiary of Breakthrough T1D to address the lack of private investment in type 1 diabetes (T1D), which created a significant gap between scientific advancements and delivery of solutions to those living with or at risk of developing T1D.

Today, our mission is to accelerate prevention, treatments, and cures for T1D by catalyzing investments in T1D-focused companies. We deliver investment and leadership support to the companies driving innovation through novel science and technology.

The Fund serves as a critical thought partner for companies throughout product development and regulatory approval by leveraging extensive Breakthrough T1D resources and expert network.

0 Invested in Variety of T1D Approaches

0 Companies Invested In

0 In Alongside Dollars Funding T1D-related Efforts

0 Total Capital Raised For Companies

The T1D Fund

A Mission-Oriented Scaled Venture Fund

We continue to reinvest any realized gains into new investments to show our conviction in our mission of curing T1D.

We are the first scaled venture fund focused on T1D in the world, with $200M+ in assets. Our expertise and leadership influences philanthropies, pharma, and other venture capital to invest billions of dollars alongside us to generate cure-oriented therapies.

0 Assets Under Management

0 Multiple On Invested Capital (Realized)

0 Successful Company Exits

The Relationship Between Breakthrough T1D (Formerly JDRF) & The T1D Fund

The T1D Fund is uniquely positioned to transform the therapeutic landscape of T1D through our investment approach.

The T1D Fund is a wholly owned, independently governed, not-for-profit subsidiary of Breakthrough T1D. This enables us to utilize the expansive network that the foundation has across all areas of treatment, from early-stage research to government advocacy. By acquiring capital through the T1D Fund’s investment, our portfolio companies can tap into the expertise across Breakthrough T1D to optimize for success.

Although separate entities with different approaches to opportunities, the T1D Fund and the foundation share the same strong mission of supporting innovation to accelerate development toward cures. Through this relationship, the T1D Fund is able to invest in the most-promising opportunities while continuing to provide support to its portfolio across the development life cycle.